Therapeutic Advances in Respiratory Disease最新文献

{"title":"From treatment to threat: the fatal impact of cumulative glucocorticoid dosage on outcomes in immunocompromised patients with community-acquired pneumonia.","authors":"Saibin Wang, Qian Ye, Yijun Sheng","doi":"10.1177/17534666251332085","DOIUrl":"https://doi.org/10.1177/17534666251332085","url":null,"abstract":"<p><strong>Background: </strong>Chronic glucocorticoid therapy is known to heighten the risk of secondary pulmonary infections. However, the impact of cumulative glucocorticoid dosage (CGD) on mortality risk in patients who develop community-acquired pneumonia (CAP) while undergoing glucocorticoid therapy remains inadequately explored.</p><p><strong>Objectives: </strong>This study aims to clarify the relationship between CGD and mortality outcomes in immunocompromised patients with CAP.</p><p><strong>Design: </strong>This study is a retrospective cohort analysis utilizing data from the DRYAD database.</p><p><strong>Methods: </strong>We examined data from 561 patients diagnosed with CAP who had received either oral or intravenous glucocorticoids prior to their CAP diagnosis. To evaluate the effect of CGD on mortality risk, we employed piecewise linear regression and Cox regression analyses, adjusting for relevant confounders.</p><p><strong>Results: </strong>Among the study population, the median CGD was 4 g of methylprednisolone (interquartile range 2.16-8.80 g). The 30-, 60-, and 90-day mortality rates were 22.28%, 25.13%, and 25.49%, respectively. Piecewise linear regression analysis revealed a nonlinear relationship between methylprednisolone dose and mortality risk, indicating a threshold effect at a methylprednisolone level of 20 g. In addition, Cox regression analysis showed a significantly higher mortality risk in patients with CGD exceeding 40 g of methylprednisolone compared to those with CGD between 20 and 40 g, after adjusting for potential confounding factors (adjusted HR 5.16, 95% CI: 1.16-22.99, <i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>CAP occurring in close proximity to recent high doses of steroids is associated with pathogens typically seen in immunocompromised hosts and is linked to higher mortality compared to usual CAP.</p>","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"19 ","pages":"17534666251332085"},"PeriodicalIF":3.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033499/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thanks to Reviewers.","authors":"","doi":"10.1177/17534666251335195","DOIUrl":"https://doi.org/10.1177/17534666251335195","url":null,"abstract":"","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"19 ","pages":"17534666251335195"},"PeriodicalIF":3.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143995889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tracheobronchial amyloidosis with Sjögren's syndrome: a case report.","authors":"Chongxiang Chen, Pingping Wang, Na Zhao, Derong Zhang, Cuifen Chen, Ping Peng","doi":"10.1177/17534666251342145","DOIUrl":"10.1177/17534666251342145","url":null,"abstract":"<p><p>We report a case of tracheobronchial amyloidosis (TBA) in a 55-year-old woman with newly diagnosed primary Sjögren's syndrome (SS), presenting with persistent cough, hemoptysis, and dry mucosal symptoms. Chest CT showed thickened airway walls and cystic lung changes, while bronchoscopy revealed nodular lesions with exposed vessels. Congo red staining confirmed amyloid deposition with κ light-chain dominance, consistent with AL amyloidosis. Despite immunosuppressive therapy, airway lesions persisted, highlighting the challenge of managing localized amyloidosis in SS. This case underscores the need for early recognition of TBA in SS patients presenting with respiratory symptoms.</p>","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"19 ","pages":"17534666251342145"},"PeriodicalIF":3.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12102560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of respiratory muscle training in improving pulmonary function and survival in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis.","authors":"María Jesús Benzo-Iglesias, Patricia Rocamora-Pérez, María de Los Ángeles Valverde-Martínez, Amelia Victoria García-Luengo, Pedro Miguel Benzo-Iglesias, Remedios López-Liria","doi":"10.1177/17534666251346095","DOIUrl":"10.1177/17534666251346095","url":null,"abstract":"<p><strong>Background: </strong>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons, resulting in muscle weakness, loss of function, and ultimately death due to respiratory failure. Due to the lethal prognosis of ALS, respiratory muscle training has been proposed as a potentially beneficial intervention.</p><p><strong>Objectives: </strong>To systematically review the efficacy of respiratory muscle training on lung function and respiratory muscle strength in ALS patients.</p><p><strong>Design: </strong>A systematic review and meta-analysis of randomized controlled trials.</p><p><strong>Data sources and methods: </strong>Articles published in PubMed, PEDro, Scopus, and Web of Science databases up to July 2024. The Preferred Reporting Items for Systematic reviews and Meta-Analyses 2020 statement guideline was followed. Included studies had (1) ALS patients, (2) respiratory muscle training, (3) physical exercise, usual care or no intervention were provided as a comparison group, (4) assessments of lung function, respiratory muscle strength, quality of life, survival, fatigue, and functional capacity outcome measures, and (5) a randomized controlled trial design. Methodological quality was analyzed using the PEDro scale, and risk of bias with the Cochrane Collaboration Risk of Bias Tool. Meta-analyses were performed with Review Manager software.</p><p><strong>Results: </strong>Five randomized controlled trials with 170 participants were included. The results showed that respiratory muscle training improved muscle strength, particularly maximum expiratory and inspiratory pressures. One study suggested inspiratory muscle training as a survival predictor in ALS patients. No significant effects were observed in forced vital capacity or quality of life. No adverse effects were reported.</p><p><strong>Conclusion: </strong>Respiratory muscle training improves ventilatory function, particularly respiratory muscle strength, in people with ALS. While evidence is limited, it shows promise as an adjuvant therapy to enhance quality of life and survival. It has been registered in the PROSPERO (CRD42024568235).</p>","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"19 ","pages":"17534666251346095"},"PeriodicalIF":3.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of exercise maintenance on mortality in interstitial lung disease: a population-based retrospective cohort study.","authors":"Bo-Guen Kim, Min Gu Kang, Sung Jun Chung, Hyun Koog Kang, Jong Seung Kim, Hyun Lee","doi":"10.1177/17534666251362380","DOIUrl":"10.1177/17534666251362380","url":null,"abstract":"<p><strong>Background: </strong>Previous studies have proposed exercise capacity as a mortality predictor in individuals with interstitial lung disease (ILD). However, limited information is available regarding whether maintaining exercise is associated with improved survival in individuals with ILD.</p><p><strong>Objectives: </strong>We aimed to evaluate the association between exercise maintenance and mortality in individuals with ILD using a longitudinal, large population-based database.</p><p><strong>Design: </strong>This retrospective cohort study used the Korean National Health Insurance claims-based database.</p><p><strong>Methods: </strong>We analyzed a total of 3850 individuals with ILD who underwent two consecutive health screening examinations. The study exposure was the change in exercise habits between the two examinations, with individuals classified as exercisers (exercise maintainers and exercise non-maintainers) or non-exercisers. The primary outcome was mortality. We adjusted for age, sex, body mass index (BMI), smoking status, alcohol status, economic status, residential area, and comorbidities.</p><p><strong>Results: </strong>During a median follow-up of 7.2 (interquartile range, 5.6-9.2) years, the incidence rate of death for exercisers was lower than that of non-exercisers (341.28 per 10,000 person-years (PY) vs 401.81 per 10,000 PY). Multivariable Cox regression analysis showed that the risk of mortality was substantially lower in exercisers compared to non-exercisers (adjusted hazard ratio (aHR): 0.82, 95% confidence interval (CI): 0.72-0.94). The risk of reduction for death was correlated with exercise adherence, with the lowest risk among exercise maintainers (aHR: 0.78 (0.66-0.92)) followed by exercise non-maintainers (aHR: 0.85 (0.73-0.99)), compared to non-exercisers. In subgroup analyses, BMI and economic status had a significant interaction in the association between exercise and mortality. The risk of death was lower in individuals with a lower BMI and higher economic status compared to their counterparts.</p><p><strong>Conclusion: </strong>Among individuals with ILD, the risk of death was inversely correlated with the level of exercise adherence, cautiously suggesting the importance of exercise maintenance in individuals with ILD.</p>","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"19 ","pages":"17534666251362380"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144837788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of performance improvement strategies on unplanned extubation in an inner-city intensive care unit.","authors":"Kriti Gupta, Luis Espinosa, Shalini Penikilapate, Sindhaghatta Venkatram, Gilda Diaz-Fuentes","doi":"10.1177/17534666251383662","DOIUrl":"https://doi.org/10.1177/17534666251383662","url":null,"abstract":"<p><strong>Background: </strong>Unplanned extubation (UE) in intensive care units (ICUs) is a significant patient safety concern, associated with increased morbidity and healthcare utilization; the reported rates of UE vary from 1% to 15%. There is sparse data on the effects of multiple performance improvement (PI) strategies to decrease the rate of UE, particularly in inner-city ICU populations. This study evaluates the impact of PI strategies on UE rates and associated patient outcomes in an adult ICU.</p><p><strong>Objectives: </strong>To determine the impact of performance improvement (PI) strategies on rates of unplanned extubation (UE), reintubation, tracheostomy, mortality, and length of hospital stay in ICU patients.</p><p><strong>Design: </strong>Retrospective cohort studyMethods:This retrospective observational study included 6,397 mechanically ventilated patients admitted to a single tertiary ICU between 2015 and 2023. Three distinct time periods were compared: Period 1 (2015-2017, pre-PI), Period 2 (2018-2020, early-PI), and Period 3 (2021-2023, sustained-PI). Demographics, sedation practices, UE characteristics, and outcomes were analyzed using logistic regression.</p><p><strong>Results: </strong>UE incidence declined significantly from 3.79% in Period 1 to 2.17% in Period 3 (<i>p</i> = 0.002). Reintubation rates dropped from 45.2% to 26.7% (<i>p</i> = 0.011), and tracheostomy rates from 19.0% to 2.2% (<i>p</i> < 0.001). Multivariate analysis showed reduced odds of reintubation in Periods 2 (OR = 0.219, <i>p</i> = 0.001) and 3 (OR = 0.345, <i>p</i> = 0.021) and reduced odds of tracheostomy in Period 3 (OR = 0.011, <i>p</i> = 0.016). Risk factors for reintubation included the absence of prior intubation history and not undergoing spontaneous breathing trials. Older age (⩾71 years) and positive urine toxicology for opiates were strongly associated with tracheostomy.</p><p><strong>Conclusion: </strong>Implementation of PI strategies significantly reduced rates of unplanned extubation, reintubation, and tracheostomy. These findings support continued quality improvement initiatives in ICU airway management.</p>","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"19 ","pages":"17534666251383662"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic model for COPD patients with nocardia infection: a study based on clinical features and risk factors.","authors":"Kai Zhang, Kangli Yang, Hongmin Wang","doi":"10.1177/17534666251359139","DOIUrl":"10.1177/17534666251359139","url":null,"abstract":"<p><strong>Background: </strong>The escalating morbidity and mortality of chronic obstructive pulmonary disease (COPD) necessitates improved diagnostic approaches for comorbid infections. COPD patients exhibit heightened susceptibility to opportunistic pathogens like Nocardia species due to compromised airway defenses and frequent glucocorticoid/immuno-suppressant use. Despite its clinical significance, Nocardia infection remains diagnostically challenging due to nonspecific presentations and imaging features.</p><p><strong>Objectives: </strong>To develop and validate a diagnostic model integrating clinical characteristics and risk factors for COPD complicated by Nocardia infection.</p><p><strong>Design: </strong>A retrospective analysis was conducted on clinical data from 586 patients diagnosed with COPD and Nocardia infection, including clinical symptoms, laboratory tests, imaging findings, and treatment outcomes. Patients were screened according to inclusion and exclusion criteria and divided into two groups: COPD with Nocardia infection group (infection group) and COPD-only group (control group).</p><p><strong>Methods: </strong>This retrospective study analyzed 586 COPD patients (2019-2024), stratified into Nocardia-infected (<i>n</i> = 289) and noninfected (<i>n</i> = 297) cohorts. Demographic, laboratory, pulmonary function, and imaging data were collected. Multivariate logistic regression identified independent predictors, which informed a nomogram model. Model performance was assessed via concordance index (C-index), calibration curves, and ROC analysis.</p><p><strong>Results: </strong>Independent risk factors included hemoptysis (OR = 1.99, 95% CI: 0.76-5.26), lymphocyte count (OR = 6.81, 95% CI: 4.06-11.42), hemoglobin (OR = 1.01, 95% CI: 0.99-1.03), and pulmonary function parameters (FEV₁/FVC ratio OR = 12.47, 95% CI: 1.25-124.16). The model demonstrated excellent discrimination (C-index: 0.895 infected, 0.829 noninfected) and calibration (mean absolute error: 0.127-0.170). ROC analysis revealed AUCs of 0.896 (95% CI: 0.90-0.97) and 0.830 (95% CI: 0.77-0.89) for infected and noninfected groups, respectively.</p><p><strong>Conclusion: </strong>This validated nomogram provides a clinically actionable tool for early Nocardia detection in COPD patients, addressing a critical diagnostic gap. External validation is warranted to confirm generalizability.</p>","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"19 ","pages":"17534666251359139"},"PeriodicalIF":3.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12280267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extrafine formulation of beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurized metered-dose inhaler in the treatment of asthma: a review.","authors":"Erminia Ridolo, Manlio Milanese, Alessandro Barone, Francesca Nicoletta, Martina Ottoni, Filippo Ferdinando Cosini, Giovanni Passalacqua, Carlo Lombardi","doi":"10.1177/17534666251332076","DOIUrl":"https://doi.org/10.1177/17534666251332076","url":null,"abstract":"<p><p>In the management of difficult-to-treat and severe asthma, the incorporation of a Long-Acting Muscarinic Antagonist (LAMA) into a regimen of Inhaled Corticosteroids plus Long-Acting β₂ agonists (ICS/LABA) represents a viable add-on therapeutic strategy. Historically, this approach required the use of separate inhalers; however, the recent advent of \"single-inhaler triple therapy\" (SITT) provided a valuable alternative. One such formulation is the extrafine combination of beclomethasone dipropionate (BDP), fluticasone furoate (FF), and glycopyrronium bromide (GB), which is delivered via a single pressurized metered-dose inhaler (pMDI). Clinical trials, including the TRIMARAN and TRIGGER studies, alongside subsequent post-hoc analyses, have elucidated the benefits of this SITT at both 87/5/9 μg and 172/5/9 μg dosing regimens administered daily. Findings indicated a significant improvement in respiratory function and a reduction in the frequency of exacerbations among patients with uncontrolled asthma. The BDP/FF/GB SITT confirmed efficacy and safety across various ethnic groups (including Caucasian, Japanese, and Chinese populations) and across different age cohorts (adults and adolescents), although it still remains unapproved for individuals under 18 years of age. The use of a single pMDI facilitates the deposition of extra- fine particles from all three active ingredients in the small airways enhancing therapeutic effectiveness. Moreover, the consolidation of medications into one device may improve patients' adherence by mitigating the risks associated with device mismanagement and ensuring optimal drug delivery. The cost-effectiveness analysis of the BDP/FF/GB SITT suggests favorable outcomes compared to traditional ICS/LABA and ICS/LABA plus tiotropium combinations. Additional data will be forthcoming from the ongoing real-life TRIMAXIMIZE observational study.</p>","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"19 ","pages":"17534666251332076"},"PeriodicalIF":3.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study.","authors":"Angela Pepe, Cristina Fevola, Daniela Dolce, Silvia Campana, Novella Ravenni, Giovanni Taccetti, Donatello Salvatore, Vito Terlizzi","doi":"10.1177/17534666251314706","DOIUrl":"10.1177/17534666251314706","url":null,"abstract":"<p><strong>Background: </strong>Cystic fibrosis (CF) is characterized by chronic neutrophilic inflammation in the airways. Elexacaftor/tezacaftor/ivacaftor (ETI) therapy has demonstrably improved clinical outcomes and quality of life in people with CF (pwCF), but its effects on systemic inflammatory parameters remain unclear.</p><p><strong>Objective: </strong>To evaluate the impact of ETI on systemic inflammation in children and adolescents with CF.</p><p><strong>Design: </strong>Retrospective, dual-center observational, propensity score-matching study of pediatric pwCF on ETI.</p><p><strong>Methods: </strong>PwCF aged ⩽ 18 years treated with ETI at two Italian reference centers were included in this study. Data on immunoglobulins (Ig) (A, G, and M), γ-globulin, leukocyte levels, percent predicted forced expiratory volume in the first second (ppFEV1), sweat chloride (SC) concentration, and sputum cultures were collected at baseline, 12, and 24 months of treatment. Laboratory data of a control group (pwCF, not in ETI therapy, same demographic characteristics as the study group) were also collected.</p><p><strong>Results: </strong>Sixty-six patients (30 males, median age: 12 years, F508del homozygous: 23) were included. Mean IgG levels (SD) significantly decreased (<i>p</i> = 0.001) from 1168.20 mg/dl (344.41) at baseline to 1093.05 mg/dl (258.73; 12 months) and 1092.87 mg/dl (232.42; 24 months). Similar reductions were observed for IgA and γ-globulin; IgM reduction was not statistically significant. Leukocyte levels also decreased significantly from 8.04 × 10³/µl (3.23 × 10³) at baseline to 6.61 × 10³/µl (1.74 × 10³) (12 months) and 6.45 × 10³/µl (1.70 × 10³; 24 months). As for the control group, no significant changes in the levels of Ig, leukocytes, and γ-globulin were detected throughout the study period (<i>p</i> > 0.05).The mean (SD) ppFEV1 and the overall mean (SD) SC concentration significantly decreased during the follow-up. Regarding cultures, 18 (27%) of the 27 patients positive (41%) for <i>Staphylococcus aureus</i> at baseline became negative during treatment. Three patients (4%) with persistently positive cultures for <i>Pseudomonas aeruginosa</i> during the first 12 months, became negative after 24 months. One patient (1.5%), with a baseline positive culture for <i>Pseudomonas Aeruginosa</i>, showed negative cultures after 12 months.</p><p><strong>Conclusion: </strong>ETI treatment improved respiratory outcomes and significantly reduced values of IgG, IgA, γ-globulin, and leukocytes, suggesting an effect on the systemic inflammatory response. Further research is warranted to elucidate the role of inflammatory parameters in monitoring response to therapy.</p>","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"19 ","pages":"17534666251314706"},"PeriodicalIF":3.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel nomogram for predicting postoperative pneumonia risk in patients with localized bronchiectasis.","authors":"Cai Yongsheng, Ke Lihui, Hao Xuefeng, Qiao Anbang, Yang Xiaoxiao, Chen Wenhui, Li Weiqing, Yang Zeng, Wei Bo","doi":"10.1177/17534666251320471","DOIUrl":"10.1177/17534666251320471","url":null,"abstract":"<p><strong>Background: </strong>Pneumonia is one of the most common complications after lung resection. However, there are currently no reports of postoperative pneumonia in patients with bronchiectasis.</p><p><strong>Objectives: </strong>Our study aims to construct a new nomogram to predict the risk of postoperative pneumonia in patients with localized bronchiectasis.</p><p><strong>Design: </strong>The clinical data of patients with localized bronchiectasis from April 2012 to August 2022 were retrospectively analyzed.</p><p><strong>Methods: </strong>Independent risk factors were identified through simple linear regression and multiple linear regression analysis, and a new nomogram was constructed based on independent risk factors. The validity of the nomogram was evaluated using the consistency index (C-index), receiver operating characteristic curve, calibration chart, and decision curve analysis chart.</p><p><strong>Results: </strong>The new nomogram prediction model included five independent risk factors: tuberculosis history, smoking history, platelet-lymphocyte ratio (PLR), diffusing capacity of the lung for carbon monoxide, and controlled nutritional status score. The area under the curve of the prediction model is 0.870 (95% CI: 0.750-0.892), showing good discrimination ability, and the probability threshold was set at 0.2013. In addition, the calibration curve shows that the nomogram has good calibration. In the decision curve, the nomogram model showed good clinical net benefit.</p><p><strong>Conclusion: </strong>This study is the first to construct a nomogram prediction model for postoperative pneumonia of localized bronchiectasis, which can more accurately and directly assess the risk probability of postoperative pneumonia, and provide certain help for clinicians in prevention and treatment decisions.</p>","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"19 ","pages":"17534666251320471"},"PeriodicalIF":3.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11848899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143484098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}